Does the neurotoxicity of haloperidol explain the higher mortality in dementia patients compared with the second generation agents?

American Journal of Psychiatry

Volumn 169, Issue 6, 2012, Pages 663-664

  Nasrallah, Henry A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE;

AGE DISTRIBUTION; APOPTOSIS; DEMENTIA; DRUG CONTRAINDICATION; DRUG EFFICACY; GERIATRIC PATIENT; HIGH RISK PATIENT; HUMAN; LETTER; MORTALITY; NEUROPROTECTION; NEUROTOXICITY; PRIORITY JOURNAL; PSYCHOSIS; VETERAN;

EID: 84862235864     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2012.12020279     Document Type: Letter

References (5)

1. Kales HC, Kim HM, Zivin K, Valenstein M, Seyfield LS, Chiang C, Cunningham F, Schneider LO, Blow FC: Risk of mortality among individual antipsychotics in patients with dementia. Am J Psychiatry 2012; 169:71-79
2. Nasrallah HA, White T, Nasrallah AT: Lower mortality in geriatric patients receiving risperidone and olanzapine versus haloperidol: a preliminary analysis of retrospective data. Am J Geriatr Psychiatry 2004; 12:437-439 (Pubitemid 38878864)
3. Gassó P, Mas S, Molina O, Bernando M, Lafuente A, Parellada E: Neurotoxic/neuroprotective activity of haloperidol, risperidone, and paliperidone in neuroblastoma cells. Prog Neuropsychopharmacol Biol Psychiatry 2012; 36:71-77
4. Newton SS, Duman RS: Neurogenic actions of atypical antipsychotic drugs and therapeutic implications. CNS Drugs 2007; 21:715-725 (Pubitemid 47294718)
5. Gil-ad I, Shtaif B, Shiloh R, Weizman A: Evolution of the neurotoxic activity of typical and atypical neuroleptics: relevance to iatrogenic extra pyramidal symptoms. Cell Mol Neurobiol 2001; 21:705-715